TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9374151

Group type: EXPERIMENTAL
Intervention: Lateral thoracodorsal flap (LTD)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Latissimus dorsi flap (LD)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Pedicled transverse rectus abdominis musculocutaneous (TRAM) flap
Number of subjects: 56

Group type: COMPARATOR
Intervention: Irradiated patients (LD and TRAM)
Number of subjects: 56
Study: 1329476

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nitrates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of Lisinopril and Nitrates
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 2414253

Group type: EXPERIMENTAL
Intervention: Bleomycin injected intramuscularly 1 hour before radiation treatment daily for 5 days a week
Number of subjects: 222

Group type: COMPARATOR
Intervention: Radiation therapy without added chemotherapy
Number of subjects: 222
Study: 30859872

Group type: EXPERIMENTAL
Intervention: TeamSTEPPS program
Number of subjects: 10

Group type: COMPARATOR
Intervention: Non-TeamSTEPPS group
Number of subjects: 10
Study: 29438370

Group type: EXPERIMENTAL
Intervention: Cobimetinib plus vemurafenib (C+V)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus vemurafenib (P+V)
Number of subjects: 0
Study: 25789594

Group type: EXPERIMENTAL
Intervention: Vitamin and trace element composition
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study: 24064933

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Nefopam
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 21960653

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) sessions (4 sessions, 30-45 minutes each) plus usual care
Number of subjects: 146

Group type: COMPARATOR
Intervention: Control group received usual care
Number of subjects: 146
Study: 19237438

Group type: EXPERIMENTAL
Intervention: Heparin-bonded catheters
Number of subjects: 87

Group type: COMPARATOR
Intervention: Standard non-heparin-bonded catheters
Number of subjects: 87
Study: 17324206

Group type: EXPERIMENTAL
Intervention: Polyquad-based care regimen
Number of subjects: 41

Group type: COMPARATOR
Intervention: PHMB-based care regimen
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Lotrafilcon A lenses
Number of subjects: 41

Group type: COMPARATOR
Intervention: Galyfilcon A lenses
Number of subjects: 41
Study: 15161390

Group type: EXPERIMENTAL
Intervention: Attentional blink induced by RSVP task
Number of subjects: 0

Group type: COMPARATOR
Intervention: Spatial cues in visual search display
Number of subjects: 0
Study: 11301617

Group type: EXPERIMENTAL
Intervention: Treatment that halves the risk of new vertebral deformities
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 8342264

Group type: EXPERIMENTAL
Intervention: Specific instructions for the early return of gastrointestinal motility (suggestion group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reassurance and nonspecific instructions (control group)
Number of subjects: 0
Study: 3534202

Group type: EXPERIMENTAL
Intervention: Oscillating air mattress (14 to 16 regular pulses per minute)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Conventional mattress
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Oscillating air mattress
Number of subjects: 122
Study: 29729957

Group type: EXPERIMENTAL
Intervention: GM-SR 4/1000 mg once-daily
Number of subjects: 168

Group type: COMPARATOR
Intervention: GM-IR 2/500 mg BID
Number of subjects: 168
Study: 27025241

Group type: EXPERIMENTAL
Intervention: Dose C (10 mg mane and 5 mg tarde)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Dose B (10 mg mane and 10 mg tarde)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Dose A (20 mg mane and 10 mg tarde)
Number of subjects: 10
Study: 25647441

Group type: EXPERIMENTAL
Intervention: Brief, structured, telephone tobacco cessation counseling (BST) delivered by clinical pharmacists.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual care (control) provided by clinical pharmacists.
Number of subjects: 120
Study: 23192454

Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum BB536
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 21364772

Group type: EXPERIMENTAL
Intervention: Dopamine (DA) therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: No DA therapy (off DA therapy)
Number of subjects: 0
Study: 19343887

Group type: EXPERIMENTAL
Intervention: OXY‐TDS (transdermal oxybutynin)
Number of subjects: 699
Study: 17217715

Group type: EXPERIMENTAL
Intervention: CHD2 group (30 patients)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: CHD3 group (30 patients)
Number of subjects: 130

Group type: COMPARATOR
Intervention: non-CHD group (39 patients)
Number of subjects: 130

Group type: COMPARATOR
Intervention: CHD1 group (30 patients)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Positive rHR (or HRR) without ST lowering during exercise
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Correlation with Duke score
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Correlation with Gensini score
Number of subjects: 130
Study: 12861415

Group type: EXPERIMENTAL
Intervention: Low-resistance/high-repetition knee extension exercise in normobaric hypoxia (FiO2 0.12)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Low-resistance/high-repetition knee extension exercise in normoxia
Number of subjects: 19
Study: 10871974

Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 or 30 mg once daily
Number of subjects: 901

Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 901

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 901
Study: 9105542

Group type: EXPERIMENTAL
Intervention: Gliquidone 30 mg tablet administered 15 min before breakfast
Number of subjects: 32
Study: 1583434

Group type: EXPERIMENTAL
Intervention: Dinamap 1846SX
Number of subjects: 293

Group type: COMPARATOR
Intervention: Hawksley random zero sphygmomanometer
Number of subjects: 293
Study: 3327018

Group type: EXPERIMENTAL
Intervention: Breathing close to total lung capacity (TLC)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Breathing close to residual volume (RV)
Number of subjects: 5
Study: 31944821

Group type: EXPERIMENTAL
Intervention: Cone beam CT (CBCT) imaging to measure the radiolucency area around the crown of impacted maxillary canines.
Number of subjects: 58
Study: 29480324

Group type: EXPERIMENTAL
Intervention: EGCG-concentrated green tea extract (GTE) low dose
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: EGCG-concentrated green tea extract (GTE) high dose
Number of subjects: 13

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 13
Study: 27144300

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation with fixed pulse amplitude for 40 minutes (Group A)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation with adjusted pulse amplitude for 40 minutes (Group B)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Exercises only (Group C)
Number of subjects: 45
Study: 25601635

Group type: EXPERIMENTAL
Intervention: GSD-SZ+TAU
Number of subjects: 101

Group type: COMPARATOR
Intervention: TAU alone
Number of subjects: 101
Study: 23843474

Group type: EXPERIMENTAL
Intervention: Biofortified pearl millet
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (non-biofortified pearl millet)
Number of subjects: 40
Study: 20969457

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 19694878

Group type: EXPERIMENTAL
Intervention: Transparent disc application (intervention group)
Number of subjects: 9762

Group type: COMPARATOR
Intervention: Finger method (control group)
Number of subjects: 9762
Study: 16505520

Group type: EXPERIMENTAL
Intervention: Parenteral group
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Oral group
Number of subjects: 54
Study: 15628112

Group type: EXPERIMENTAL
Intervention: Pharmacologically treated APE patients
Number of subjects: 36

Group type: COMPARATOR
Intervention: Age-matched controls (30 subjects, 12 men, 18 women, age 67 ± 12 years)
Number of subjects: 36
Study: 11348882

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/d)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Combination therapy (Atorvastatin and bile acid sequestrant)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 9009924

Group type: EXPERIMENTAL
Intervention: Continuous lip bumper therapy for 6 months
Number of subjects: 34

Group type: COMPARATOR
Intervention: Nontreatment (control group) for 6 months
Number of subjects: 34
Study: 8392282

Group type: EXPERIMENTAL
Intervention: Captopril 6.25 mg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Enalapril 2.5 mg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Perindopril 2.0 mg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Enalaprilat 1.5 mg (intravenous)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Perindoprilat 1.0 mg (intravenous)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo (oral or intravenous)
Number of subjects: 72
Study: 3946263

Group type: EXPERIMENTAL
Intervention: Low-intensity training (42 to 60% of baseline VO2 max, average heart rate 102 to 122 beats/min)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: High-intensity training (63 to 81% of baseline VO2 max, average heart rate 128 to 148 beats/min)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (no exercise training)
Number of subjects: 64
Study: 31202749

Group type: EXPERIMENTAL
Intervention: Baseline ESS
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: IVUS-derived plaque characteristics
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Low ESS
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Plaque burden
Number of subjects: 44

Group type: COMPARATOR
Intervention: IVUS-derived plaque characteristics with ESS
Number of subjects: 44

Group type: COMPARATOR
Intervention: OCT variables and ESS
Number of subjects: 44
Study: 29460547

Group type: EXPERIMENTAL
Intervention: Zinc plus octenidine
Number of subjects: 10
Study: 27412269

Group type: EXPERIMENTAL
Intervention: Tubaramure program (food rations, health service promotion, behavior change communication)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tubaramure program
Number of subjects: 0
Study: 24671453

Group type: EXPERIMENTAL
Intervention: Oral rabeprazole 20 mg twice daily for 5 days before ESD
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo administered twice daily for 5 days before ESD
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intragastric pH measurement
Number of subjects: 120
Study: 23678499

Group type: EXPERIMENTAL
Intervention: Home-visiting programme targeting infant attachment
Number of subjects: 120
Study: 20832103

Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 143

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 143
Study: 19062727

Group type: EXPERIMENTAL
Intervention: Dose-dense chemotherapy with paclitaxel (175 mg/m2) and epirubicin (60 mg/m2) every two weeks
Number of subjects: 101

Group type: COMPARATOR
Intervention: Regular chemotherapy with paclitaxel (175 mg/m2) and epirubicin (60 mg/m2) every three weeks
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Dose-dense chemotherapy
Number of subjects: 101

Group type: COMPARATOR
Intervention: Regular chemotherapy
Number of subjects: 101
Study: 15452681

Group type: EXPERIMENTAL
Intervention: Isradipine with low dose methamphetamine (15 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isradipine with high dose methamphetamine (30 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isradipine without methamphetamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control) with low dose methamphetamine (15 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control) with high dose methamphetamine (30 mg)
Number of subjects: 0
Study: 12593523

Group type: EXPERIMENTAL
Intervention: Beclometasone dipropionate (BDP) suspension for nebulization 1,600 microg day(‐1) b.i.d. (n = 75)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Beclometasone dipropionate (BDP) spray 800 microg day(‐1) b.i.d. via metered-dose inhaler (MDI) plus spacer (n = 76)
Number of subjects: 151
Study: 10578788

Group type: COMPARATOR
Intervention: Routine nipple care including an ointment (control group)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Avoidance of nipple creams and other products (intervention group)
Number of subjects: 219
Study: 8554224

Group type: EXPERIMENTAL
Intervention: 23‐polyvalent pneumococcal polysaccharide vaccine
Number of subjects: 30
Study: 1677625

Group type: EXPERIMENTAL
Intervention: PGE2 vaginal tablets
Number of subjects: 200

Group type: COMPARATOR
Intervention: PGE2 vaginal pessaries
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: PGE2 vaginal tablets and PGE2 vaginal pessaries
Number of subjects: 200
Study: 6129951

Group type: EXPERIMENTAL
Intervention: Clonidine (oral)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Propanolol (oral)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Metoprolol (IV)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Clonidine (IV) and Metoprolol (IV) combined
Number of subjects: 27
Study: 31704535

Group type: EXPERIMENTAL
Intervention: Biofeedback training for balance control (2-week duration)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Usual exercises (waitlist control)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Healthy controls (N=25)
Number of subjects: 35
Study: 30439785

Group type: EXPERIMENTAL
Intervention: 100 mg metoprolol
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 28549319

Group type: EXPERIMENTAL
Intervention: Diode laser (660nm, 200mW, continuous mode, time of irradiation: 32s, energy density: 4J/cm2, spot size: 0.5cm) applied immediately after FGG surgery and on days 1, 2, 4, and 7 post-surgery.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Laser-off control group receiving the same sequence of irradiation without laser.
Number of subjects: 12
Study: 27083334

Group type: EXPERIMENTAL
Intervention: Afatinib (40 mg per day)
Number of subjects: 319

Group type: COMPARATOR
Intervention: Gefitinib (250 mg per day)
Number of subjects: 319
Study: 25163103

Group type: EXPERIMENTAL
Intervention: Mental Health Treatment Study (MHTS) intervention including individual placement and support supported employment (IPS‐SE), systematic medication management (SMM), and additional behavioral‐health services (OBH)
Number of subjects: 2238

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 2238
Study: 21761999

Group type: EXPERIMENTAL
Intervention: Carbetocin (single dose)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Oxytocin (infusion)
Number of subjects: 110
Study: 19256733

Group type: EXPERIMENTAL
Intervention: Musical story with distraction
Number of subjects: 76

Group type: COMPARATOR
Intervention: Spoken story with distraction
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Musical story with no distraction
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Spoken story with no distraction
Number of subjects: 76
Study: 16881500

Group type: EXPERIMENTAL
Intervention: Ametop (amethocaine gel) applied to a digit for 30 minutes before capillary sampling
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (digit on the opposing hand without Ametop)
Number of subjects: 22
Study: 15023708

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray
Number of subjects: 299
Study: 11349825

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil/HCTZ, 16/12.5 mg once daily
Number of subjects: 328

Group type: COMPARATOR
Intervention: Candesartan cilexetil/placebo, 16 mg once daily
Number of subjects: 328
Study: 9475307

Group type: EXPERIMENTAL
Intervention: ARF‐treated porridge
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard porridge liquefied with water
Number of subjects: 30
Study: 7937827

Group type: EXPERIMENTAL
Intervention: Deuterium-labeled RRR-alpha-tocopherol
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Deuterium-labeled SRR-alpha-tocopherol
Number of subjects: 9

Group type: COMPARATOR
Intervention: Difference in fractional disappearance rates between RRR and SRR in controls
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: RRR-alpha-tocopherol recycling
Number of subjects: 9
Study: 3278436

Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional immunosuppressive therapy
Number of subjects: 0
Study: 30948278

Group type: EXPERIMENTAL
Intervention: Rose aroma (5 drops of 40% rose aroma)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Benson relaxation technique
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Combined rose aroma and Benson relaxation
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 132
Study: 28358168

Group type: EXPERIMENTAL
Intervention: 250 U BTX‐B
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 1,000 U BTX‐B
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 2,000 U BTX‐B
Number of subjects: 45

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 45
Study: 25059736

Group type: EXPERIMENTAL
Intervention: Graduated compression stockings
Number of subjects: 69

Group type: COMPARATOR
Intervention: No graduated compression stockings (Control)
Number of subjects: 69
Study: 23276469

Group type: EXPERIMENTAL
Intervention: Continuous antiretroviral therapy
Number of subjects: 3085

Group type: EXPERIMENTAL
Intervention: hsCRP
Number of subjects: 3085

Group type: EXPERIMENTAL
Intervention: IL-6
Number of subjects: 3085

Group type: EXPERIMENTAL
Intervention: D-dimer
Number of subjects: 3085
Study: 21576196

Group type: EXPERIMENTAL
Intervention: Rosiglitazone for 6 months
Number of subjects: 34

Group type: COMPARATOR
Intervention: No additional treatment (Control)
Number of subjects: 34
Study: 17526621

Group type: EXPERIMENTAL
Intervention: Plyometric training on sand
Number of subjects: 37

Group type: COMPARATOR
Intervention: Plyometric training on grass
Number of subjects: 37
Study: 14985966

Group type: EXPERIMENTAL
Intervention: Dopexamine (2.25 microg/kg per min)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Fenoterol (at least 0.025 microg/kg per min)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 27
Study: 12467536

Group type: EXPERIMENTAL
Intervention: rhGH (0.3 IU/kg) injected percutaneously every evening for ten days since the 1st postoperative day (POD)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no rhGH treatment)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: rhGH group
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 9438269

Group type: EXPERIMENTAL
Intervention: Actovegin (250 ml 20%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7805666

Group type: EXPERIMENTAL
Intervention: Upper arm cuff pressures applied randomly between 0 and 25 mmHg for 15 min
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Different forearm positions (-18, 0, 18, 36, 54 cm relative to heart level)
Number of subjects: 12
Study: 2779970

Group type: EXPERIMENTAL
Intervention: Epinephrine in the irrigating fluid
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Acetylcholine intracameral
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 39
Study: 788744

Group type: EXPERIMENTAL
Intervention: Nisoxetine (10-20 mg b.d. for 7 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31221143

Group type: EXPERIMENTAL
Intervention: Groups 4 Health (G4H)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 200
Study: 28662613

Group type: EXPERIMENTAL
Intervention: Modified World Health Organization ORS (group A)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Commercially available ORS (DripDrop; group B)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 28
Study: 26397431

Group type: EXPERIMENTAL
Intervention: Nurse support during recovery
Number of subjects: 0
Study: 23401566

Group type: EXPERIMENTAL
Intervention: DVD-delivered exercise intervention
Number of subjects: 307

Group type: COMPARATOR
Intervention: Healthy aging, attentional control
Number of subjects: 307
Study: 21616540

Group type: EXPERIMENTAL
Intervention: Aerobic physical exercise (16.5 kcal/kg/week, three times a week during hospitalization)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aerobic physical exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 19803573

Group type: EXPERIMENTAL
Intervention: Cultural congruence in treatment
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Enhanced specialty referral model
Number of subjects: 272

Group type: COMPARATOR
Intervention: Integrated primary care model
Number of subjects: 272
Study: 16940452

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy at a mean maintenance dose of 0.31 mg/d in elderly GHD patients
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy at a mean maintenance dose of 0.44 mg/d in younger GHD patients
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (elderly GHD patients)
Number of subjects: 48
Study: 14525770

Group type: EXPERIMENTAL
Intervention: Itraconazole (oral solution 2.5 mg/kg 3 times daily, or intravenous 200 mg daily)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Fluconazole (400 mg/d)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 304

Group type: COMPARATOR
Intervention: Fluconazole
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Overall survival and fungal-free survival
Number of subjects: 304
Study: 11380123

Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation
Number of subjects: 47

Group type: COMPARATOR
Intervention: Closed treatment in a plaster cast
Number of subjects: 47
Study: 8981381

Group type: EXPERIMENTAL
Intervention: Auditory Evoked Responses (AERs) using two-tone non-speech stimuli with temporal lags (TOT)
Number of subjects: 16